LEADERSHIP

Bernard Gilly, CEO at BrainEver – Pioneering first-in-class therapies for neurodegenerative diseases (ALS, Parkinson’s)

Bernard GILLY

Chief Executive Officer

Alain Prochiantz, CSO at BrainEver – Pioneering homeoprotein-based therapies for neurodegenerative diseases | Collège de France Professor

Alain PROCHIANTZ

Chief Scientific Officer

Claire Friedel, Chief Project Officer at BrainEver – Driving innovation in ALS & Parkinson’s drug development

Claire FRIEDEL

Chief Project Officer

Anne Bousseau, CMO at BrainEver – Leading clinical development for neurodegenerative disease therapies

Anne BOUSSEAU

Chief Medical Officer

Bernard GILLY

Chief Executive Officer

Alain PROCHIANTZ

Chief Scientific Officer

Claire FRIEDEL

Chief Project Officer

Anne BOUSSEAU

Chief Medical Officer

Hubert MECHAIN

Chief Technical Officer

LEADERSHIP

LEADERSHIP

Bernard GILLY

Chairman and CEO

Alain PROCHAINTZ

Chief Scientific Officer (CSO)

Claire FRIEDEL

Project Officer (CPO)

Anne BOUSSEAU

Chief Medical Officer (CMO)

Hubert MECHAIN

Chief Technological and Manufacturing Officer (CTMO)

BOARD OF DIRECTORS

Bernard GILLY

Chairman

Alexia PEROUSE

Director, representative of iBionext Growth Fund participations

Benoit BARTEAU

Director, Representative of Bpifrance Investissement participations

Bervin BOUANI

Observer, representative of Turenne Capital participations

Claire FRIEDEL

Project Officer (CPO)

Anne BOUSSEAU

Chief Medical Officer (CMO)

Hubert MECHAIN

Chief Technological and Manufacturing Officer (CTMO)

Claire FRIEDEL

Project Officer (CPO)

Anne BOUSSEAU

Chief Medical Officer (CMO)

Hubert MECHAIN

Chief Technological and Manufacturing Officer (CTMO)